Fenofibrate in Type 2 Diabetes
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 2/8/2019 |
| Start Date: | February 4, 2019 |
| End Date: | June 30, 2019 |
| Contact: | Misti J Leyva, PhD |
| Email: | leyva@musc.edu |
| Phone: | 8437921933 |
Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms
Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once
in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in
diabetic retinopathy offers an important translational research opportunity. The
investigator's global proteomic study will provide new clues as to how fenofibrate protects
vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.
in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in
diabetic retinopathy offers an important translational research opportunity. The
investigator's global proteomic study will provide new clues as to how fenofibrate protects
vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.
Inclusion Criteria:
- Type 2 diabetes of at least one year's duration; stable glycemic control (no more than
1.0% change in HbA1c in the previous six months, but no limit on HbA1c)
- Triglycerides >150 mg/dL (in the previous six months)
Exclusion Criteria:
- Previous use of Fenofibrate or other fibrates
- Pregnancy
- Active malignancy
- Recent cardiac event or congestive heart failure
- Active liver disease
- Significant renal impairment (serum creatinine > 2mg/dl)
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Phone: 843-792-1933
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
